Onconetix, Inc.
ONCO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | -0.00 | -0.00 |
| FCF Yield | -72.70% | -52.09% | -141.05% | -12.44% |
| EV / EBITDA | -0.44 | -5.21 | -1.07 | -0.54 |
| Quality | ||||
| ROIC | -58.42% | -12.75% | -91.21% | -146.15% |
| Gross Margin | 88.55% | 66.20% | 45.10% | 92.70% |
| Cash Conversion Ratio | 0.36 | 0.59 | 0.23 | 0.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,069,523.71% | 1,098,785.65% | 1,243,938.39% | 1,361,458.91% |
| Free Cash Flow Growth | -125.33% | 29.47% | -117.00% | 19.79% |
| Safety | ||||
| Net Debt / EBITDA | 0.08 | -3.95 | -0.90 | -0.29 |
| Interest Coverage | -6.90 | -8.68 | -56.22 | -117.36 |
| Efficiency | ||||
| Inventory Turnover | 0.23 | 0.24 | 0.36 | 0.81 |
| Cash Conversion Cycle | -4,278.51 | -6,021.16 | -3,853.26 | -6,431.33 |